PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

BACKGROUND: Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have recently shown promising activity and tolerable toxicity in pre-treated NSCLC patients. However the predictive role of PD-L1 express...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Passiglia, Francesco, Bronte, Giuseppe, Bazan, Viviana, Natoli, Clara, Rizzo, Sergio, Galvano, Antonio, Listì, Angela, Cicero, Giuseppe, Rolfo, Christian, Santini, Daniele, Russo, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991415/
https://ncbi.nlm.nih.gov/pubmed/26918451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7582
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados